<DOC>
	<DOCNO>NCT00200850</DOCNO>
	<brief_summary>This study investigate sublingual immunotherapy ( SLIT ) , treatment involve antigen placement tongue help asthma sufferer build tolerance allergy-causing substance . Specifically , study determine effectiveness SLIT two different dose regimens patient intermittent mild asthma cause dust mite .</brief_summary>
	<brief_title>Immunotherapy Administered Under Tongue Treat Dust Mite Allergy</brief_title>
	<detailed_description>Asthma serious lung condition lead cause long-term illness child . Many common household substance trigger worsen asthma attack . It important people reduce household allergen learn effective treatment specific type asthma . Inhaled short-acting beta agonist albuterol standard treatment mild , intermittent asthma . However , recent study show add allergen-specific immunotherapy current asthma therapy help control asthma symptom . This study determine safety effectiveness SLIT two different dose regimen treat patient house dust mite-induced allergic rhinitis/mild intermittent asthma . Participants randomly assign receive low dose SLIT , high dose SLIT , placebo least 12 month . House dsut mite-induced allergy skin test perform study entry , select timepoints throughout study , end study . The test determine whether SLIT create immune tolerance state well whether SLIT act via local systemic immunological system .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>House dust miteinduced allergic rhinitis/mild intermittent asthma Use previous allergy immunotherapy house dust mite asthma Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Breathing</keyword>
	<keyword>Allergy</keyword>
	<keyword>Mites , House Dust</keyword>
</DOC>